Renasant Bio

Executive Summary

Renasant Bio is a private biotech company pioneering small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD), a leading genetic cause of end-stage renal failure with no approved disease-modifying therapies. Founded in 2019 and based in Memphis, the company aims to restore polycystin 1/2 function to halt disease progression. Although no specific pipeline details are disclosed, Renasant Bio targets the root cause of ADPKD, addressing a significant unmet need. The company's stage is listed as 'Approved,' which may indicate prior regulatory interaction or a misclassification; however, given the early-stage nature of the field, Renasant Bio is likely in preclinical or early clinical development. With ADPKD affecting ~140,000 patients in the US alone, Renasant Bio's approach has the potential to capture a substantial market if clinical success is achieved.

Upcoming Catalysts (preview)

• Q4 2026IND Filing or Clinical Trial Application70% success
• Q3 2026Preclinical Proof-of-Concept Data Release60% success
• TBDStrategic Partnership or Licensing Deal50% success